NOT KNOWN FACTUAL STATEMENTS ABOUT HEMGENIX

Amount of qualified clients: CDEC reviewed the uncertainty in the volume of individuals with moderately critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some people who will be labeled as acquiring delicate or reasonable disease may have a intense bleeding

Number of qualified sufferers: CDEC reviewed the uncertainty in the amount of individuals with moderately critical to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific authorities consulted by CADTH indicated that some sufferers who will be classified as having gentle or average ailment may have a severe bleeding